![Nanna Liebach Lüneborg](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nanna Liebach Lüneborg
Directeur/Membre du Conseil chez
MAPLIGHT THERAPEUTICS, INC.
Profil
Nanna Liebach Lüneborg currently serves as Independent Director at BioInvent International AB since 2022, Director at Avilex Pharma ApS, Director at Numab Therapeutics AG since 2021, Director at Glionova AB, Director at Stargazer Pharmaceuticals, Inc., Director at Inversago Pharma, Inc., Independent Director at MapLight Therapeutics, Inc. starting 2025, Director at Sparrow Pharmaceuticals, Inc., Director at F2g Inc., Director at Noema Pharma Us, Inc., Principal at Novo Seeds, General Partner at Forbion Capital Partners Management Holding BV since 2021, and Observer at Galecto Biotech ApS.
Former roles include Investment Director at Novo Seeds from 2013 to 2015, Director at Strategic Partners A, MinervaX ApS, PCOVERY ApS, ObsEva SA, NBE-Therapeutics AG, Affinicon ApS, ReViral Ltd., IO Biotech ApS, Inventiva SA, Non-Executive Director at LAVA Therapeutics NV from 2021 to 2022, Director at NodThera Ltd., Director at Epsilon-3 Bio Ltd, Partner at Novo Holdings A from 2018 to 2021, Research Manager at Cancer Research UK, Associate at Apposite Capital LLP from 2008 to 2012, Member-Supervisory Board at Inthera Bioscience AG, and Principal at Novo Ventures 1 A from 2016 to 2018.
Education includes undergraduate studies at the University of Oxford, an MBA from the University of Cambridge, and a doctorate from University College London.
Postes actifs de Nanna Liebach Lüneborg
| Sociétés | Poste | Début |
|---|---|---|
| MAPLIGHT THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/07/2025 |
| BIOINVENT INTERNATIONAL AB | Directeur/Membre du Conseil | 12/07/2022 |
Stargazer Pharmaceuticals, Inc.
 Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical drugs | Directeur/Membre du Conseil | - |
Numab Therapeutics AG
 Numab Therapeutics AG BiotechnologyHealth Technology Develops antibody-based immunotherapies for inflammation and cancer | Directeur/Membre du Conseil | 20/05/2021 |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion is an active manager invest companies located in Northwest Europe and the United States. The firm focuses on companies operating in the fields of life sciences and biomedical technology. It participates in early stage capital requirements with an investment size ranging from EUR 1 - 7 million. It participates in follow-on investments, takes a board seat and acts as lead investor. | Private Equity Investor | 01/09/2021 |
Avilex Pharma ApS
 Avilex Pharma ApS BiotechnologyHealth Technology Operates as a clinical stage company that develops neuroprotectants | Directeur/Membre du Conseil | - |
Inversago Pharma, Inc.
 Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops CB1 receptor based therapies for obesity, diabetes and complication treatment | Directeur/Membre du Conseil | - |
Sparrow Pharmaceuticals, Inc.
 Sparrow Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Directeur/Membre du Conseil | - |
F2g Inc.
 F2g Inc. Miscellaneous Commercial ServicesCommercial Services F2g Inc. is a biopharmaceutical and biotechnology company specializing in the discovery and development of novel antifungal therapies targeting rare, life-threatening fungal infections. The company is based in Princeton, NJ. The company leverages proprietary genomic and molecular biology technologies to develop small-molecule inhibitors, such as orotomides, which selectively inhibit fungal dihydroorotate dehydrogenase (dhodh), a key enzyme essential for fungal DNA, RNA, and protein synthesis. This mechanism induces fungal cell death and differs from existing antifungals that primarily inhibit fungal growth. The company's lead drug candidate, olorofim, targets invasive fungal infections such as invasive aspergillosis and coccidioidomycosis (valley fever), addressing unmet medical needs related to antifungal resistance, immunosuppressant use, and climate change. F2g’s pipeline includes oral and other formulations for rare, highly resistant mold infections affecting immunocompromised patients. The company offers an early access program for investigational therapies and maintains transparency through media updates, investor communications, and detailed information on its leadership, governance, scientific research, and the fungal disease landscape. | Directeur/Membre du Conseil | - |
Anciens postes connus de Nanna Liebach Lüneborg
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░ ░░ ░░░░ ░░░ ░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Nanna Liebach Lüneborg
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
70
Relations au 1er degré
32
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 32 |
|---|---|
BioInvent International AB
 BioInvent International AB BiotechnologyHealth Technology Develops and manufactures immunomodulatory antibodies for cancer treatment | Health Technology |
Novo Holdings A/S (Denmark)
 Novo Holdings A/S (Denmark) Investment ManagersFinance Functions as an alternative investment manager | Finance |
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University College London
 University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion is an active manager invest companies located in Northwest Europe and the United States. The firm focuses on companies operating in the fields of life sciences and biomedical technology. It participates in early stage capital requirements with an investment size ranging from EUR 1 - 7 million. It participates in follow-on investments, takes a board seat and acts as lead investor. | Finance |
Cancer Research UK
 Cancer Research UK Miscellaneous Commercial ServicesCommercial Services Provides cancer research services | Commercial Services |
Apposite Capital LLP
 Apposite Capital LLP Investment ManagersFinance Apposite Capital invests in companies located in the United Kingdom and European with revenues of up to EUR 100 million. The firm focuses on the technology sector. It provides financing for MBOs, buy-ins and growth capital requirements. It also acquires minority interest. | Finance |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures invests in companies located in Europe, the United States and Asia. The firm targets companies operating in the fields of health technology, health services, biotechnology and medical specialties sectors. It provides financing for early stage capital requirements. | Finance |
Novo Seeds
 Novo Seeds Investment ManagersFinance Novo Seeds invests in companies located in Europe and the United States. The fund targets companies operating in the fields of life science and healthcare technology sectors. It provides financing for seed and early stage capital requirement. | Finance |
Strategic Partners A/S
 Strategic Partners A/S Pharmaceuticals: MajorHealth Technology Provides therapeutic treatment of of diseases caused by defects in the function and metabolism of proteins | Health Technology |
Minervax ApS
 Minervax ApS Pharmaceuticals: MajorHealth Technology Develops prophylactic vaccines for pregnant women and older adults | Health Technology |
Pcovery ApS
 Pcovery ApS Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of invasive fungal infections | Health Technology |
Epsilon-3 Bio Ltd
 Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Provides compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders | Health Technology |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Manufactures galectin modulators for the treatment of severe diseases which includes fibrosis and cancer | Health Technology |
Avilex Pharma ApS
Avilex Pharma ApS BiotechnologyHealth Technology Operates as a clinical stage company that develops neuroprotectants | Health Technology |
ObsEva SA
 ObsEva SA Pharmaceuticals: MajorHealth Technology Provides therapeutic treatments to increase women's reproductivity | Health Technology |
Numab Therapeutics AG
Numab Therapeutics AG BiotechnologyHealth Technology Develops antibody-based immunotherapies for inflammation and cancer | Health Technology |
NBE-Therapeutics AG
 NBE-Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops antibody drug conjugates and advancing targeted cancer therapies | Health Technology |
Affinicon ApS
 Affinicon ApS Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products | Health Technology |
Glionova AB
 Glionova AB BiotechnologyHealth Technology Develops cancer treatment drugs | Health Technology |
Inthera Bioscience AG
 Inthera Bioscience AG BiotechnologyHealth Technology Develops, manufactures small bio molecule therapies for solid tumors | Health Technology |
ReViral Ltd.
 ReViral Ltd. BiotechnologyHealth Technology Develops novel antiviral therapeutics | Health Technology |
IO Biotech ApS
 IO Biotech ApS BiotechnologyHealth Technology Develops disruptive immune therapies | Health Technology |
Inventiva SA
 Inventiva SA BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops oral small molecule therapies for the treatment of MASH and other diseases | Health Technology |
Stargazer Pharmaceuticals, Inc.
Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical drugs | Health Technology |
LAVA Therapeutics NV
 LAVA Therapeutics NV Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops antibodies for the treatment of cancer | Health Technology |
NodThera Ltd.
 NodThera Ltd. BiotechnologyHealth Technology Operates biotechnology company which discovers and develops new treatments for diseases driven by chronic inflammation | Health Technology |
Inversago Pharma, Inc.
Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops CB1 receptor based therapies for obesity, diabetes and complication treatment | Health Technology |
MapLight Therapeutics, Inc.
 MapLight Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics for debilitating central nervous system disorders | Health Technology |
Sparrow Pharmaceuticals, Inc.
Sparrow Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
F2g Inc.
F2g Inc. Miscellaneous Commercial ServicesCommercial Services F2g Inc. is a biopharmaceutical and biotechnology company specializing in the discovery and development of novel antifungal therapies targeting rare, life-threatening fungal infections. The company is based in Princeton, NJ. The company leverages proprietary genomic and molecular biology technologies to develop small-molecule inhibitors, such as orotomides, which selectively inhibit fungal dihydroorotate dehydrogenase (dhodh), a key enzyme essential for fungal DNA, RNA, and protein synthesis. This mechanism induces fungal cell death and differs from existing antifungals that primarily inhibit fungal growth. The company's lead drug candidate, olorofim, targets invasive fungal infections such as invasive aspergillosis and coccidioidomycosis (valley fever), addressing unmet medical needs related to antifungal resistance, immunosuppressant use, and climate change. F2g’s pipeline includes oral and other formulations for rare, highly resistant mold infections affecting immunocompromised patients. The company offers an early access program for investigational therapies and maintains transparency through media updates, investor communications, and detailed information on its leadership, governance, scientific research, and the fungal disease landscape. | Commercial Services |
